How the Oncostatin M receptor helps drive pancreatic cancer
Oncostatin M Receptor in Pancreatic Adenocarcinoma
This project looks at whether blocking the Oncostatin M receptor can slow aggressive pancreatic ductal adenocarcinoma in people.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Portland VA Medical Center NIH-funded |
| Lab location | 1 site (Portland, United States) |
| Project ID | NIH-11118675 on NIH RePORTER |
What this research studies
Researchers study tumor samples from people with pancreatic cancer and use laboratory models to see how Oncostatin M (OSM) and its receptor (OSMR) change cancer cells and the surrounding support cells. They will measure OSMR levels in patient tumors, manipulate OSM/OSMR signaling in cancer cells and fibroblasts, and observe effects on stem-cell behaviors, invasion, and metabolism. The team will also test whether interrupting this signaling reduces features that make tumors resistant to treatment.
Who could benefit from this research
Good fit: Ideal candidates would be people living with pancreatic ductal adenocarcinoma, particularly those with tumors that show high OSMR activity or advanced disease.
Not a fit: People without pancreatic cancer or whose tumors lack OSM/OSMR activity are unlikely to benefit directly from this work.
Why it matters
Potential benefit: If successful, this work could point to new treatments that target OSM/OSMR to slow tumor growth or make existing therapies work better.
How similar studies have performed: Prior laboratory studies show OSM can promote aggressive tumor traits and poor outcomes, but directly targeting OSMR is a newer approach with limited clinical testing so far.
Where this research is happening
Portland, United States
- Portland VA Medical Center — Portland, United States (Active)
Researchers
- Principal investigator: Zimmers, Teresa a — Portland VA Medical Center
- Study coordinator: Zimmers, Teresa a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.